Nippon India Pharma Fund Direct-Growth
NAV
₹577.7651
as on 04 Dec 2025, 09:00 PM
₹2.7869(0.48%)
Last Change
Scheme Information
Nippon India Pharma Fund Direct-Growth
as of 31 Oct 2025, 05:30 AM
₹8,346.49 Cr
0.91%
0.33%
Open-End
Growth
Exit load of 1% if redeemed within 1 month.
BSE Healthcare Total Return Index
View
Sectors Holding in this Mutual Fund
Healthcare
99.67%
₹8,318.95 Cr
Others
0.33%
₹27.54 Cr
Healthcare
99.67%
₹8,318.95 Cr
Others
0.33%
₹27.54 Cr
Sun Pharmaceutical Industries Ltd.
12.57%
₹1,049.15 Cr
Divi's Laboratories Ltd.
9.49%
₹792.08 Cr
Lupin Ltd.
5.82%
₹485.77 Cr
Cipla Ltd.
5.62%
₹469.07 Cr
Dr. Reddy's Laboratories Ltd.
5.49%
₹458.22 Cr
Others
61.01%
₹5,092.19 Cr
Sun Pharmaceutical Industries Ltd.
12.57%
₹1,049.15 Cr
Divi's Laboratories Ltd.
9.49%
₹792.08 Cr
Lupin Ltd.
5.82%
₹485.77 Cr
Cipla Ltd.
5.62%
₹469.07 Cr
Dr. Reddy's Laboratories Ltd.
5.49%
₹458.22 Cr
Others
61.01%
₹5,092.19 Cr
Funds in this Category
This fund's returns: 21.83%
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct - Growth
Min. Investment
₹100
27.57
Category Returns
18.78%
27.57%
3Y Returns
27.57 %
SBI Healthcare Opportunities Fund Direct Plan-Growth
Min. Investment
₹500
24.95
Category Returns
18.78%
27.57%
3Y Returns
24.95 %
UTI Healthcare Fund Direct-Growth
Min. Investment
₹500
24.59
Category Returns
18.78%
27.57%
3Y Returns
24.59 %
About Nippon India Pharma Fund Direct-Growth
Nippon India Pharma Fund Direct-Growth scheme return performance in last 1 year is 0.54%, in last 3 years is 81.03% and 722.99% since scheme launch. The min. SIP amount to invest in this scheme is ₹100.
Scheme Details
| AUM: | ₹8,346.49 Cr |
| Category: | Equity: Sectoral-Pharma |
| Launch Date: | Invalid date |
| Fund Type: | Open-End |
AMC Information
Nippon India Mutual Fund
Address
Investment Performance
₹ 1,00,000
would have given a return of
₹1,10,871
₹1,21,647
₹1,76,246
₹1,81,025
Bank Account
Fixed Deposit
Regular Mutual Fund
This Fund on Paytm Money
This Mutual Fund
Profit (absolute return)
₹81,025
81.03%
Investment Returns
Scheme Riskometer
Investors understand that their principal will be at very high risk